Patents by Inventor David W. Osborne

David W. Osborne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12257242
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: September 12, 2023
    Date of Patent: March 25, 2025
    Assignee: ARCUTIS Biotherapeutics, Inc.
    Inventor: David W. Osborne
  • Publication number: 20250049771
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Application
    Filed: June 17, 2024
    Publication date: February 13, 2025
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 12144802
    Abstract: Topical pharmaceutical compositions comprising roflumilast and solvents that are capable of dissolving high amounts of roflumilast. The pharmaceutical compositions are capable of dissolving high amounts of roflumilast relative to other commonly used solvents in approved topical pharmaceutical compositions. The solvents are particularly useful when combined with water to maintain high levels of dissolved roflumilast, which is highly insoluble in water.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: November 19, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David W. Osborne, Babak N. Tofig, Frank Watanabe
  • Publication number: 20240374576
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Application
    Filed: May 22, 2024
    Publication date: November 14, 2024
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 12083122
    Abstract: The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin. In a particularly preferred embodiment, the active ingredient is SHR0302.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: September 10, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 12053481
    Abstract: Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: August 6, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David W. Osborne, Babak N. Tofig
  • Patent number: 12042487
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: July 23, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 12042558
    Abstract: Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: July 23, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 12005052
    Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: June 11, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 12005051
    Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: June 11, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 11992480
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: May 28, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David W. Osborne, Howard Welgus
  • Publication number: 20240024300
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 25, 2024
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 11819496
    Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: November 21, 2023
    Assignee: Arcutis Biotherapeutics, Inc.
    Inventor: David W. Osborne
  • Patent number: 11793796
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: October 24, 2023
    Assignee: Arcutis Biotherapeutics, Inc.
    Inventor: David W. Osborne
  • Patent number: 11730740
    Abstract: The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin. In a particularly preferred embodiment, the active ingredient is SHR0302.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: August 22, 2023
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 11707454
    Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: July 25, 2023
    Assignee: Arcutis Biotherapeutics, Inc.
    Inventors: David Reuben Berk, Patrick Eugene Burnett, Saori Kato, David W. Osborne
  • Patent number: 11628177
    Abstract: Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: April 18, 2023
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David W. Osborne, Babak N. Tofig
  • Publication number: 20230091358
    Abstract: The low aqueous solubility of roflumilast in parenteral preparations and topical emulsions, suspensions, gels or solutions can be improved by including a blend of water-miscible solvents in the pharmaceutical composition. The blend of water-miscible solvents can include diethylene glycol monoethyl ether (Tradename Transcutol®; abbreviated DEGEE) and water. The ratio of diethylene glycol monoethyl ether to water is from 1:10 to 20:1. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 23, 2023
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Patent number: 11534493
    Abstract: The low aqueous solubility of roflumilast in parenteral preparations and topical emulsions, suspensions, gels or solutions can be improved by including a blend of water-miscible solvents in the pharmaceutical composition. The blend of water-miscible solvents can include diethylene glycol monoethyl ether (Tradename Transcutol®; abbreviated DEGEE) and water. The ratio of diethylene glycol monoethyl ether to water is from 1:10 to 20:1. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 27, 2022
    Assignee: Arcutis Biotherapeutics, Inc.
    Inventor: David W. Osborne
  • Patent number: 11129818
    Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: September 28, 2021
    Assignee: Arcutis Biotherapeutics, Inc.
    Inventors: David W. Osborne, Bhaskar Chaudhuri, Archie W. Thurston, Jr.